These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
181 related items for PubMed ID: 25414371
1. Magnetic resonance imaging of microvascular obstruction in hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation. Amano Y, Kitamura M, Yamada F, Aita K, Takayama M, Tachi M, Kumita S. Acta Radiol; 2015 Nov; 56(11):1323-8. PubMed ID: 25414371 [Abstract] [Full Text] [Related]
2. Successful percutaneous transluminal septal myocardial ablation through a right superior septal artery for a patient with hypertrophic obstructive cardiomyopathy. Kurita T, Tsuchikane E, Tanaka N, Suzuki T. Cardiovasc Interv Ther; 2015 Oct; 30(4):377-81. PubMed ID: 25502014 [Abstract] [Full Text] [Related]
3. Ameliorating the severity of sleep-disordered breathing concomitant with heart failure status after percutaneous transluminal septal myocardial ablation for drug-refractory hypertrophic obstructive cardiomyopathy. Akita K, Maekawa Y, Kohno T, Tsuruta H, Murata M, Fukuda K. Heart Vessels; 2017 Nov; 32(11):1320-1326. PubMed ID: 28555387 [Abstract] [Full Text] [Related]
6. Long term exercise capacity in patients with hypertrophic cardiomyopathy treated with percutaneous transluminal septal myocardial ablation. Malek LA, Chojnowska L, Klopotowski M, Maczynska R, Demkow M, Witkowski A, Kusmierczyk B, Piotrowicz E, Konka M, Dabrowski M, Ruzyllo W. Eur J Heart Fail; 2008 Nov; 10(11):1123-6. PubMed ID: 18840395 [Abstract] [Full Text] [Related]
7. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy; The Chinese experience in 119 patients from a single center. Li ZQ, Cheng TO, Zhang WW, Qiao SB, Zhao LY, Jin YZ, Guan RM, Liu L. Int J Cardiol; 2004 Feb; 93(2-3):197-202. PubMed ID: 14975547 [Abstract] [Full Text] [Related]
9. Reverse remodeling after percutaneous transluminal septal myocardial ablation in severe but asymptomatic LVOT obstruction (RASTA) study: Rationale and design of transcatheter septal reduction in asymptomatic patients with severe hypertrophic obstructive cardiomyopathy. Arslan F, Akdim F, Ten Berg JM. Catheter Cardiovasc Interv; 2021 Feb 15; 97(3):488-492. PubMed ID: 32808736 [Abstract] [Full Text] [Related]
10. Percutaneous transluminal septal myocardial ablation: past, present, and future. Maekawa Y, Takamisawa I, Takano H, Takayama M. J Cardiol; 2022 Sep 15; 80(3):211-217. PubMed ID: 34924238 [Abstract] [Full Text] [Related]
11. Percutaneous versus surgical treatment for patients with hypertrophic obstructive cardiomyopathy and enlarged anterior mitral valve leaflets. van der Lee C, ten Cate FJ, Geleijnse ML, Kofflard MJ, Pedone C, van Herwerden LA, Biagini E, Vletter WB, Serruys PW. Circulation; 2005 Jul 26; 112(4):482-8. PubMed ID: 16027255 [Abstract] [Full Text] [Related]
13. Early remodelling of left ventricle and improvement of myocardial performance in patients after percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy. Veselka J, Honek T. Int J Cardiol; 2003 Mar 26; 88(1):27-32. PubMed ID: 12659981 [Abstract] [Full Text] [Related]
14. Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery. Qin JX, Shiota T, Lever HM, Kapadia SR, Sitges M, Rubin DN, Bauer F, Greenberg NL, Agler DA, Drinko JK, Martin M, Tuzcu EM, Smedira NG, Lytle B, Thomas JD. J Am Coll Cardiol; 2001 Dec 26; 38(7):1994-2000. PubMed ID: 11738306 [Abstract] [Full Text] [Related]
15. Evaluation of left ventricular myocardial perfusion and function using gated SPECT in patients with hypertrophic obstruction cardiomyopathy following percutaneous transluminal septal myocardial ablation. Zhang L, Liu R, Qiao SB, Sun XX, He ZX, Tian YQ. Nucl Med Commun; 2014 Jul 26; 35(7):762-6. PubMed ID: 24681766 [Abstract] [Full Text] [Related]
16. Effect of septal ablation on regional diastolic dysfunction and diastolic asynchrony in patients with hypertrophic obstructive cardiomyopathy: a follow-up study using speckle tracking echocardiography. Chen S, Duan F, Yuan J, Qiao S, Lv X, Hu F, Yang W, Zhang J, Yang Y. Echocardiography; 2013 May 26; 30(5):564-71. PubMed ID: 23305549 [Abstract] [Full Text] [Related]
18. Complications of percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy. Zhang W, Li Z, Zhang M, Yuan L, Guan R, Hou A, Jin Y, Deng Z. Chin Med J (Engl); 2002 Sep 26; 115(9):1283-6. PubMed ID: 12411095 [Abstract] [Full Text] [Related]
19. Real-world clinical outcomes of percutaneous transluminal septal myocardial ablation for patients with drug-refractory hypertrophic obstructive cardiomyopathy: results from a retrospective multicenter registry of non-high-volume centers. Nakamura K, Toba T, Otake H, Kakizaki S, Fujimoto D, Takahashi Y, Fukuyama Y, Kawamori H, Tanaka H, Takaya T, Iwasaki M, Kozuki A, Kawai H, Hayashi T, Shite J, Hirata KI. Heart Vessels; 2022 Nov 26; 37(11):1937-1946. PubMed ID: 35641828 [Abstract] [Full Text] [Related]
20. [Long-term outcome of patients with hypertrophic obstructive cardiomyopathy post percutaneous transluminal septal ablation]. Zheng SW, Shi HY, Dai JJ, Chen H, Wu WH, Qiu XB. Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Apr 24; 48(4):294-301. PubMed ID: 32370480 [Abstract] [Full Text] [Related] Page: [Next] [New Search]